Perspective Therapeutics (CATX) investor relations material

Patient impact and clinical results

• Demonstrated significant tumor reduction in neuroendocrine cancer patients using VMT-α-NET, with some achieving near-complete responses after four doses.

• Achieved a 44% overall response rate and 81% progression-free survival at one year in SSTR2-positive tumors, with a strong safety profile and no serious adverse events.

• Melanoma program showed prolonged disease stability at 3-millicurie dose, with no major adverse events and potential synergy with checkpoint inhibitors.

• FAP-α program targets a broad range of solid tumors, leveraging high tumor retention and rapid accumulation for effective stroma targeting.

• Imaging with lead-203 enables precise patient selection and dosimetry, optimizing therapeutic outcomes and minimizing off-target effects.

Technology and platform differentiation

• Utilizes a proprietary chelator and peptide-based delivery system for lead-212, optimizing biodistribution and minimizing kidney uptake.

• Lead-212 offers a potent, short-lived alpha payload with a 10-hour half-life, balancing efficacy and safety while enabling same-day delivery.

• Elemental twin lead-203 allows for pre-therapy imaging, ensuring accurate targeting and patient selection.

• Platform supports multiple programs, including SSTR2, MC1R, and FAP-α, with a robust pipeline and ongoing first-in-human studies.

• IP portfolio covers composition of matter, chelator technology, and scalable manufacturing processes.

Manufacturing, supply chain, and scalability

• Vertically integrated model covers discovery, clinical development, isotope production, and commercial manufacturing.

• End-to-end manufacturing network with facilities in New Jersey, Iowa, and expansion into Chicago, Houston, and LA ensures reliable supply.

• Stockpiles thorium-228, enabling years of uninterrupted isotope supply and reducing risk of shortages.

• Same-day shelf life for lead-212 products necessitates a distributed network for timely delivery to hospitals.

• Collaboration with the U.S. Department of Energy and international partners secures upstream isotope sources.